Equillium, Inc. has obtained the necessary regulatory clearances in Australia to move forward with its first-in-human study of EQ504, a development that sets the stage for the company's next step in clinical development. The company announced on October 5, 2026, that it received approval from the Human Research Ethics Committee and clearance from the Therapeutic Goods Administration under the Clinical Trial Notification scheme. Equillium expects to begin dosing healthy participants by early November 2026.
The trial is a single-center investigation using a randomized, double-blinded, and placebo-controlled design. Its primary goal is to assess how safe and tolerable EQ504 is, while also measuring how the drug behaves in the body and what biological changes it triggers. The study will test once-daily oral doses ranging from 0.1 to 3.0 mg in healthy participants.
The research is divided into three specific components. Part A, known as the Single Ascending Dose phase, will use five sequential groups of participants to establish initial safety limits and pharmacokinetic profiles. Part B, the Multiple Ascending Dose phase, will evaluate three groups receiving daily doses for ten days to check for steady-state levels and cumulative tolerance. This section includes collecting tissue samples from the gastrointestinal tract to verify that the drug works locally. A key focus will be measuring Cytochrome P450 1A1 expression, with data intended to confirm localized activity before a future Phase 2 proof-of-concept study. Part C is a crossover group designed to see how a high-fat meal affects the drug's absorption and overall exposure.
Bruce D. Steel, Chief Executive Officer of Equillium, signed the Form 8-K current report filed with the U.S. Securities and Exchange Commission. The Delaware-incorporated company is based in La Jolla, California, and its common stock trades on the Nasdaq Capital Market under the ticker EQ.
The filing contains forward-looking statements about the development of EQ504, including expected timelines for dosing and data reporting. Equillium notes that these statements are subject to risks and uncertainties outside its control, which could cause actual results to differ materially. Identified risks include the company's ability to execute its plans, risks related to performing clinical studies, whether results will validate safety and efficacy, changes in the competitive landscape, and the ability to raise sufficient financing to advance EQ504. The company undertakes no obligation to update these statements except as required by law.